SC
UTHR icon

Steven Cohen’s United Therapeutics UTHR Stock Holding History

Steven Cohen’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,800
Closed -$6.4M – 4614
2026
Q1 		$6.4M Buy
+10,800
New +$5.38M 0.01% 1538
2018
Q2 		– Sell
-40,700
Closed -$4.57M – 1193
2018
Q1 		$4.57M Buy
+40,700
New +$5.17M 0.02% 594

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Steven Cohen's UTHR Position: Q2 2026 in Review

Steven Cohen increased its United Therapeutics (UTHR) stake by 35% in Q2 2026, buying an estimated $29.2M and bringing the position to 201,159 shares worth $109M. The position accounts for 0.12% of the portfolio, ranked #181.

Steven Cohen first reported a position in UTHR in Q3 2014 and has held it in 23 quarters since. 874 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Steven Cohen held 201,159 shares of United Therapeutics worth $109M as of Q2 2026.
  • Steven Cohen bought 51,856 United Therapeutics shares in Q2 2026, an estimated $29.2M.
  • United Therapeutics made up 0.12% of Steven Cohen's portfolio in Q2 2026, its #181 holding.
  • Steven Cohen first reported a position in United Therapeutics in Q3 2014 and has held it in 23 quarters since.
  • 874 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.